The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).
 
Elizabeth Lee
Honoraria - AADi
Consulting or Advisory Role - AADi; Genmab; OnCusp Therapeutics
Research Funding - AADi (Inst); Genmab (Inst); KSQ Therapeutics (Inst); Merck (Inst); OnCusp Therapeutics (Inst); ProfoundBio (Inst); Repare Therapeutics (Inst); Seagen (Inst)
 
Yinglu Zhou
No Relationships to Disclose
 
Andrea Wahner Hendrickson
Consulting or Advisory Role - Oxcia
Research Funding - Amgen (Inst); Elucida Oncology; ProLynx (Inst); Torl Biotherapeutics
 
Gini Fleming
Research Funding - Abbvie (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Duality Biologics (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Roche (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst)
 
Carolyn Krasner
No Relationships to Disclose
 
Panagiotis Konstantinopoulos
Consulting or Advisory Role - AADi; Alkermes; Artios; AstraZeneca; Bayer; Gilead Sciences; Immunogen; Kadmon; Merck; Mersana; Mural Oncology; Nimbus Therapeutics; Novartis; Pfizer/EMD Serono; Repare Therapeutics; Scorpion Therapeutics; Tesaro; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb/Sanofi (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); tesaro (Inst)
 
Elizabeth Stover
Patents, Royalties, Other Intellectual Property - Patent pending
 
Neil Horowitz
Patents, Royalties, Other Intellectual Property - Up to Date author
 
Rebecca Porter
Honoraria - OncLive Clinical Congress Consultants
Consulting or Advisory Role - Cullinan Oncology
 
Alexi Wright
Stock and Other Ownership Interests - Microsoft
Consulting or Advisory Role - Cancer Support Community; ConcertAI; Merck
Research Funding - Pack Health (Inst)
 
Ursula Matulonis
Honoraria - Alkermes; Symphogen
Consulting or Advisory Role - Agenus; Allarity Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Curelab Oncology; Eisai; GlaxoSmithKline; Immunogen; Lilly; Merck; NextCure; ProfoundBio; Tango Therapeutics
Speakers' Bureau - Med Learning Group
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Immunogen
 
Niya Xiong
No Relationships to Disclose
 
Hannah Sawyer
No Relationships to Disclose
 
Nabihah Tayob
No Relationships to Disclose
 
Joyce Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cullinan Oncology; Daiichi Sankyo; Deciphera; Eisai; Genentech/Roche; GlaxoSmithKline; LoxoLilly; Zentalis
Research Funding - 2X Oncology (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); Pfizer (Inst); Regeneron (Inst); Systimmune (Inst); Zentalis (Inst)